Name: in vitro enzyme measurement to test pharmacological chaperone responsiveness in fabry and pompe disease
Uploaded: 2017-12-20T14:00:00
Description: Watch this Scientific Journal Video about In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease at JoVE.com

Los autores desean reconocer la Loebert Mandy y Tina Czajka excelente soporte técnico. Agradecemos Flora Luo (Harvard Medical School, Boston, MA, USA) lengua ayuda de edición.

1. preparación del mutante pcDNA3.1/GLA y pcDNA3.1/GAA construcciones
Nota: Las estrategias de clonación de GLA y GAA codificación secuencias (cds) han sido reportados de15,anterior18.
<ol>
	<li>Mutagénesis sitio-dirigida mediante mutagénesis sitio-dirigida
	<ol>
		<li>Uso la referencia de las secuencias NM_000169.2 y NM_000152.4 como plantillas para la mutagénesis de los genes GLA y ...

<ol>
	<li>Ishii, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mutant+alpha-galactosidase+A+enzymes+identified+in+Fabry+disease+patients+with+residual+enzyme+activity:+biochemical+characterization+and+restoration+of+normal+intracellular+processing+by+1-deoxygalactonojirimycin.">Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.</a> Biochem J. 406, 285-295 (2007).</li><li>Tajima, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Structural+and+biochemical+studies+on+Pompe+disease+and+a+&amp;#34;pseudodeficiency+of+acid+alpha-glucosidase&amp;#34.">Structural and biochemical studies on Pompe disease and a &amp;#34;pseudodeficiency of acid alpha-glucosidase&amp;#34.</a> J Hum Genet. 52, 898-906 (2007).</li><li>Lukas, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Functional+and+Clinical+Consequences+of+Novel+&#945;-Galactosidase+A+Mutations+in+Fabry+Disease.">Functional and Clinical Consequences of Novel &#945;-Galactosidase A Mutations in Fabry Disease.</a> Hum Mutat. 37, 43-51 (2016).</li><li>Parenti, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Treating+lysosomal+storage+diseases+with+pharmacological+chaperones:+from+concept+to+clinics.">Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.</a> EMBO Mol Med. 1, 268-279 (2009).</li><li>Yasuda, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Fabry+disease:+characterization+of+alpha-galactosidase+A+double+mutations+and+the+D313Y+plasma+enzyme+pseudodeficiency+allele.">Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.</a> Hum Mutat. 22, 486-492 (2003).</li><li>Shimotori, M., Maruyama, H., Nakamura, G., Suyama, T., Sakamoto, F., Itoh, M., Miyabayashi, S., Ohnishi, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Novel+mutations+of+the+GLA+gene+in+Japanese+patients+with+Fabry+disease+and+their+functional+characterization+by+active+site+specific+chaperone.">Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone.</a> Hum Mutat. 29, 331 (2008).</li><li>Andreotti, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Therapy+of+Fabry+disease+with+pharmacological+chaperones:+from+in+silico+predictions+to+in+vitro+tests.">Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.</a> Orphanet J Rare Dis. 6, 66 (2011).</li><li>Khanna, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+pharmacological+chaperone+AT2220+increases+the+specific+activity+and+lysosomal+delivery+of+mutant+acid+alpha-glucosidase,+and+promotes+glycogen+reduction+in+a+transgenic+mouse+model+of+Pompe+disease.">The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.</a> PLoS One. 9, e102092 (2014).</li><li>Siekierska, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=&#945;-Galactosidase+aggregation+is+a+determinant+of+pharmacological+chaperone+efficacy+on+Fabry+disease+mutants.">&#945;-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.</a> J Biol Chem. 287, 28386-28397 (2012).</li><li>Parenti, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pharmacological+enhancement+of+mutated+alpha-glucosidase+activity+in+fibroblasts+from+patients+with+Pompe+disease.">Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease.</a> Mol Ther. 15, 508-514 (2007).</li><li>Wu, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+pharmacogenetic+approach+to+identify+mutant+forms+of+&#945;-galactosidase+A+that+respond+to+a+pharmacological+chaperone+for+Fabry+disease.">A pharmacogenetic approach to identify mutant forms of &#945;-galactosidase A that respond to a pharmacological chaperone for Fabry disease.</a> Hum Mutat. 32, 965-977 (2011).</li><li>Lukas, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Functional+characterisation+of+alpha-galactosidase+a+mutations+as+a+basis+for+a+new+classification+system+in+fabry+disease.">Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.</a> PLoS Genet. 9, e1003632 (2013).</li><li>Andreotti, G., Citro, V., Correra, A., Cubellis, M. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+thermodynamic+assay+to+test+pharmacological+chaperones+for+Fabry+disease.">A thermodynamic assay to test pharmacological chaperones for Fabry disease.</a> Biochim Biophys Acta. 1840, 1214-1224 (2014).</li><li>. Available from: <a target="_blank" href="https://www.google.ch/patents/US9095584">https://www.google.ch/patents/US9095584</a> (2017)</li><li>Lukas, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Enzyme+enhancers+for+the+treatment+of+Fabry+and+Pompe+disease.">Enzyme enhancers for the treatment of Fabry and Pompe disease.</a> Mol Ther. 23, 456-4564 (2015).</li><li>Yam, G. H., Bosshard, N., Zuber, C., Steinmann, B., Roth, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pharmacological+chaperone+corrects+lysosomal+storage+in+Fabry+disease+caused+by+trafficking-incompetent+variants.">Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.</a> Am J Physiol Cell Physiol. 290, C1076-C1082 (2006).</li><li>Shin, S. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Screening+for+pharmacological+chaperones+in+Fabry+disease.">Screening for pharmacological chaperones in Fabry disease.</a> Biochem Biophys Res Commun. 359, 168-173 (2007).</li><li>Shin, S. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prediction+of+response+of+mutated+alpha-galactosidase+A+to+a+pharmacological+chaperone.">Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.</a> Pharmacogenet Genomics. 18, 773-7780 (2008).</li><li>Filoni, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Functional+studies+of+new+GLA+gene+mutations+leading+to+conformational+Fabry+disease.">Functional studies of new GLA gene mutations leading to conformational Fabry disease.</a> Biochim Biophys Acta. 1802, 247-252 (2010).</li><li>Citro, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Large+Phenotypic+Spectrum+of+Fabry+Disease+Requires+Graduated+Diagnosis+and+Personalized+Therapy:+A+Meta-Analysis+Can+Help+to+Differentiate+Missense+Mutations.">The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.</a> Int J Mol Sci. 17, (2016).</li><li>Cammisa, M., Correra, A., Andreotti, G., Cubellis, M. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Fabry_CEP:+a+tool+to+identify+Fabry+mutations+responsive+to+pharmacological+chaperones.">Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones.</a> Orphanet J Rare Dis. 8, 111 (2013).</li><li>Leinekugel, P., Michel, S., Conzelmann, E., Sandhoff, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Quantitative+correlation+between+the+residual+activity+of+beta-hexosaminidase+A+and+arylsulfatase+A+and+the+severity+of+the+resulting+lysosomal+storage+disease.">Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease.</a> Hum Genet. 88, 513-523 (1992).</li><li>Germain, D. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Safety+and+pharmacodynamic+effects+of+a+pharmacological+chaperone+on+&#945;-galactosidase+A+activity+and+globotriaosylceramide+clearance+in+Fabry+disease:+report+from+two+phase+2+clinical+studies.">Safety and pharmacodynamic effects of a pharmacological chaperone on &#945;-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.</a> Orphanet J Rare Dis. 7, 91 (2012).</li><li>Hughes, D. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Oral+pharmacological+chaperone+migalastat+compared+with+enzyme+replacement+therapy+in+Fabry+disease:+18-month+results+from+the+randomised+phase+III+ATTRACT+study.">Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.</a> J Med Genet. 54, 288-296 (2017).</li><li>Parenti, G., Andria, G., Valenzano, K. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pharmacological+Chaperone+Therapy:+Preclinical+Development,+Clinical+Translation,+and+Prospects+for+the+Treatment+of+Lysosomal+Storage+Disorders.">Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.</a> Mol Ther. 23, 1138-1148 (2015).</li><li>Parenti, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+Chaperone+Enhances+Blood+&#945;-Glucosidase+Activity+in+Pompe+Disease+Patients+Treated+With+Enzyme+Replacement+Therapy.">A Chaperone Enhances Blood &#945;-Glucosidase Activity in Pompe Disease Patients Treated With Enzyme Replacement Therapy.</a> Mol Ther. 22, 2004-2012 (2014).</li></ol>

El protocolo descrito en el presente documento ofrece resultados robustos para la evaluación de daños de la enzima en enfermedades lisosomales hereditarias del metabolismo. Este manuscrito es que una enmienda al protocolo publicado anterior15. Las modificaciones más importantes implican rigor (es decir, en el proceso de preparación de construcción de vector mutante), normalización del Protocolo de la cultura de célula (es decir, las condiciones de mantenimiento y transfecc...

Hay más de una docena trastornos de lysosomal del almacenaje (LSDs) relacionados con la disfunción glucosidasa como resultado de mutaciones en el gen primario. Fabry (OMIM #301500) y la enfermedad de Pompe (OMIM #232300), más de 500 y 200 mutaciones sin sentido ha informado de1,2,3 , respectivamente, que corresponde a cerca del 60% de la cuenta total mutación. Numerosas nuevas variantes de genes todavía están siendo identificadas, muchos de los cuales tienen desconocido significado. Estudios bioquímicos revelaron que ciertos genotipos no conducen a una pérdida de función completa del gen GLA (OMIM * 300644) en la enfermedad de Fabry, pero hacer que la enzima correspondiente para no llegar a un estado plegado termodinámicamente favorecido4 . Esto resulta en retención de ER y degradación prematura de la enzima funcional de lo contrario. Conclusiones similares han sido elaborados en otras LSDs como Pompe enfermedad5. Por otra parte, la caracterización molecular de las variantes de la enzima puede facilitar la interpretación clínica de las mutaciones en el momento del diagnóstico6, sugiriendo que la progresión de la LSD es un proceso individual basado en la naturaleza de la mutación. Por lo tanto, la clasificación convencional en diferentes tipos clínicos típicamente de 2 a 3 debe ser reevaluada para optimizar el asesoramiento clínico y decisiones terapéuticas.
La terapia de reemplazo de la enzima (ERT) está disponible para ambas enfermedades. ERT, sin embargo, ha limitado eficacia en tejidos/órganos afectados como cerebro y músculo esquelético. Además, ERT puede provocar una respuesta inmunogénica que ponga en peligro sus beneficios terapéuticos. Chaperonas farmacológicas (PC) son una alternativa de tratamiento atractiva para los pacientes con mutaciones sensibles supuestos. PC sirve como un andamio molecular para el plegamiento de la proteína correcta y estabilización que a su vez impide la retención del retículo endoplásmico (ER) y ER-asociados de degradación de la enzima. Además, el PC puede administrarse por vía oral y es potencialmente capaces de cruzar la barrera hematoencefálica. Por lo tanto, la PCT puede ser una opción más viable para el tratamiento de pacientes con ciertos genotipos. Una extensa revisión sobre la aplicación de PC en LSDs, consulte la excelente revisión por Parenti7.
El descubrimiento de cientos de enfermedades que causan alelos del mutante desafía a pruebas de drogas clínico previo y requiere una evaluación sencilla, rápida y altamente estandarizada de pacientes susceptibles de un enfoque de la medicina personalizada. Con el fin de evaluar los efectos perjudiciales de las mutaciones de gene de LSD y probar mutaciones del candidato para predecir a pacientes susceptibles para el PCT, era un sistema altamente estandarizados sobreexpresión en células HEK293H que permite la medición de la actividad enzimática rápida y fiable desarrollado. Sistemas de expresión similares se han descrito previamente para la enfermedad de Fabry y Pompe con COS-78,9,10,11, HeLa células12o HEK29313 ,14,15,16 células para el gen de la glucosidasa.
Un método muy similar incluso ha sido patentado como "Método para predecir la respuesta al tratamiento farmacológico acompañante de enfermedades"17 que indica la relevancia de una célula sistema capaz de integrarse a la práctica clínica de la cultura.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Material</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>QuikChange II XL Site-Directed Mutagenesis Kit&#160;</td>
			<td>Stratagene, La Jolla, CA, USA</td>
			<td>#200522</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GLA[R301Q]-frw: 5&#180;- CTA ATG ACC TCC AAC ACA TCA GCC C-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GLA[R301Q]-rev: 5&#180;- GGG CTG ATG TGT TGG AGG TCA TTA G-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GLA[A156V]-frw: 5&#180;-CTA CGA CAT TGA TGT CCA GAC CTT TGC TG-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GLA[A156V]-rev: 5&#180;-CAG CAA AGG TCT GGA CAT CAA TGT CGT AG-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GLA[A156V]-frw: 5&#180;-GGA AAT AAA ACC TGC ACA GGC TTC CCT GGG A-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GLA[A143T]-rev: 5&#180;-TCC CAG GGA AGC CTG TGC AGG TTT TAT TTC C-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GAA[F455Y]-frw: 5&#180;-CTG CCG GGA GCT TCA GGC CCT ACG A-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GAA[F455Y]-rev: 5&#180;-TCG TAG GGC CTG AAG CTC CCG GCA G-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GAA[P545L]-frw: 5&#180;-CAC CCT ACG TGC TTG GGG TGG TTG G-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GAA[P545L]-rev: 5&#180;-CCA ACC ACC CCA AGC ACG TAG GGT G-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GAA[L552P]-frw: 5&#180;-TTG GGG GGA CCC CCC AGG CGG CCA C-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer GAA[P545L]-rev: 5&#180;-GTG GCC GCC TGG GGG GTC CCC CCA A-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer T7: 5&#180;-TAA TAC GAC TCA CTA TAG GG-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Primer BGHrev: 5&#180;-TAG AAG GCA CAG TCG AGG-3&#180;</td>
			<td>MWG Eurofins Operon, Ebersberg, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Tryptone</td>
			<td>Carl Roth, Karlsruhe, Germany</td>
			<td>8952.1</td>
			<td></td>
		</tr>
		<tr>
			<td>Yeast Extract</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>103,753</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium chloride</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>1,064,041,000</td>
			<td></td>
		</tr>
		<tr>
			<td>Potasium chloride</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>1,049,360,500</td>
			<td></td>
		</tr>
		<tr>
			<td>MgCl2 x 6H2O</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>1,058,330,250</td>
			<td></td>
		</tr>
		<tr>
			<td>D (+)-Glucose monohydrate</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>1,083,422,500</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium Hydroxide</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>1,064,980,500</td>
			<td></td>
		</tr>
		<tr>
			<td>Glycine</td>
			<td>Carl Roth, Karlsruhe, Germany</td>
			<td>3908.2</td>
			<td></td>
		</tr>
		<tr>
			<td>Citric acid</td>
			<td>Carl Roth, Karlsruhe, Germany</td>
			<td>X863.3</td>
			<td></td>
		</tr>
		<tr>
			<td>disodium hydrogen phosphate</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>1,065,860,500</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium acetate</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>1,062,640,050</td>
			<td></td>
		</tr>
		<tr>
			<td>Glacial acetic acid</td>
			<td>Sigma Aldrich, Munich, Germany</td>
			<td>A6283</td>
			<td></td>
		</tr>
		<tr>
			<td>LB Agar</td>
			<td>Carl Roth, Karlsruhe, Germany</td>
			<td>X969.2</td>
			<td></td>
		</tr>
		<tr>
			<td>LB Medium</td>
			<td>Carl Roth, Karlsruhe, Germany</td>
			<td>X968.2</td>
			<td></td>
		</tr>
		<tr>
			<td>Zyppy Plasmid Miniprep Kit</td>
			<td>ZymoResearch, Freiburg, Germany</td>
			<td>D4020</td>
			<td></td>
		</tr>
		<tr>
			<td>QIAfilter Plasmid Midi Kit</td>
			<td>Qiagen, Hilden, Germany</td>
			<td>12245</td>
			<td></td>
		</tr>
		<tr>
			<td>HEK293H cell line</td>
			<td>Invitrogen, Karlsruhe, Germany</td>
			<td>11631-017&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>Dulbecco&#180;s Modified Eagle Medium&#160;</td>
			<td>Invitrogen, Karlsruhe, Germany</td>
			<td>31966-047</td>
			<td></td>
		</tr>
		<tr>
			<td>HyClone fetal bovine serum&#160;</td>
			<td>GE Healthcare, South Logan, Utah, USA</td>
			<td>SV30160.03</td>
			<td></td>
		</tr>
		<tr>
			<td>Penicillin/streptomycin</td>
			<td>Invitrogen, Karlsruhe, Germany</td>
			<td>15140-122</td>
			<td></td>
		</tr>
		<tr>
			<td>CELLSTAR Standard Cell Culture Flasks, Greiner Bio One</td>
			<td>VWR International GmbH, Hannover, Germany</td>
			<td>82050-854</td>
			<td></td>
		</tr>
		<tr>
			<td>Cell culture plates (24 well)</td>
			<td>Sarstedt, N&#252;mbrecht, Germany</td>
			<td>831,836</td>
			<td></td>
		</tr>
		<tr>
			<td>Cellstar 96 well plate</td>
			<td>Greiner bio one, Frickenhausen, Germany</td>
			<td>655185</td>
			<td></td>
		</tr>
		<tr>
			<td>SafeSeal reaction tubes, 1,5mL&#160;</td>
			<td>Sarstedt, N&#252;mbrecht, Germany</td>
			<td>72,706</td>
			<td></td>
		</tr>
		<tr>
			<td>Lipofectamine 2000</td>
			<td>Invitrogen, Karlsruhe, Germany</td>
			<td>11668-019</td>
			<td></td>
		</tr>
		<tr>
			<td>1-Deoxygalactonojirimycin Hydrochloride&#160;</td>
			<td>Sigma Aldrich, Munich, Germany</td>
			<td>D9641</td>
			<td></td>
		</tr>
		<tr>
			<td>1-Deoxygalactonojirimycin Hydrochloride&#160;</td>
			<td>Toronto Research Chemicals, Toronto, Canada</td>
			<td>D236500</td>
			<td></td>
		</tr>
		<tr>
			<td>1-Deoxynojirimycin&#160;</td>
			<td>Sigma Aldrich, Munich, Germany</td>
			<td>D9305</td>
			<td></td>
		</tr>
		<tr>
			<td>PBS Dulbecco w/o Calcium, w/o Magnesium</td>
			<td>Biochrom, Berlin, Germany</td>
			<td>L 1825</td>
			<td></td>
		</tr>
		<tr>
			<td>Trypsin-EDTA (0.05%), phenol red</td>
			<td>Thermo Scientific, Braunschweig, Germany</td>
			<td>25300054</td>
			<td></td>
		</tr>
		<tr>
			<td>Pierce BCA Protein Assay Kit</td>
			<td>Thermo Scientific, Braunschweig, Germany</td>
			<td>23225</td>
			<td></td>
		</tr>
		<tr>
			<td>4-Methylumbelliferone</td>
			<td>Sigma Aldrich, Munich, Germany</td>
			<td>M1381</td>
			<td></td>
		</tr>
		<tr>
			<td>4-Methylumbelliferyl &#945;-D-galactopyranoside</td>
			<td>Sigma Aldrich, Munich, Germany</td>
			<td>M7633</td>
			<td></td>
		</tr>
		<tr>
			<td>4-Methylumbelliferyl &#945;-D-glucopyranoside</td>
			<td>Sigma Aldrich, Munich, Germany</td>
			<td>M9766</td>
			<td></td>
		</tr>
		<tr>
			<td>Name</td>
			<td>Company</td>
			<td>Catalog Number</td>
			<td>Comments</td>
		</tr>
		<tr>
			<td>Equipment</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>incubator type T6</td>
			<td>Heraeus Instruments, Hanau, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Luminous Plate Gr. 2 E</td>
			<td>Carl Roth, Karlsruhe, Germany</td>
			<td>P265.1</td>
			<td></td>
		</tr>
		<tr>
			<td>3130 xl Genetic Analyzer&#160;</td>
			<td>Applied Biosystems, Darmstadt, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>GFL-3032 bacterial shaker</td>
			<td>GFL, Burgwedel, Germany&#160;</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Avanti J-25 centrifuge</td>
			<td>Beckman/Coulter, Krefeld, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Ultraspec 3100 pro Spectrophotometer</td>
			<td>Amersham Biosciences, Buckinghamshire, United Kingdom</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>water-jacket incubator&#160;</td>
			<td>Binder, Tuttlingen, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Vortex Genie 1 touch mixer</td>
			<td>Scientific Industries, Bohemia, NY, USA</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Z 233 MK-2 refrigerated microtube centrifuge</td>
			<td>Hermle, Tuttlingen, Germany&#160;</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>LaboStar ultrapure water device</td>
			<td>Siemens, Berlin, Germany</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Thermo Shaker PST-60HL-4 orbital shaker</td>
			<td>Biosan, Riga, Latvia</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Tecan GENios Reader</td>
			<td>Tecan, M&#228;nnedorf, Switzerland</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>HI 223 Microprocessor pH Meter</td>
			<td>HANNA Instruments, Arvore, Portugal</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>CASY 
			Cell Counter + Analyser System 
			Model TT</td>
			<td>Innovatis AG, Cham/Zug, Switzerland</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Name</td>
			<td>Company</td>
			<td>Catalog Number</td>
			<td>Comments</td>
		</tr>
		<tr>
			<td>Software</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Magellan data analysis software v6.6</td>
			<td>Tecan, M&#228;nnedorf, Switzerland</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>GraphPad Prism 5.04</td>
			<td>GraphPad Software, Inc., La Jolla, CA; USA</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Microsoft Office 2010</td>
			<td>Microsoft Corporation, Redmond, WA, USA</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>BioEdit Alignment Editor, V7.0.1</td>
			<td>http://www.mbio.ncsu.edu/bioedit/bioedit.html</td>
			<td>n.a.</td>
			<td></td>
		</tr>
		<tr>
			<td>Abbreviations</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>frw = forward; rev = reverse</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>n.a. = not applicable</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
	</tbody>
</table>

in vitro enzyme measurement to test pharmacological chaperone responsiveness in fabry and pompe disease

El uso de la medicina personalizada para tratar enfermedades monogénicas raras como trastornos de depósito lisosomal (LSDs) es desafiado por diseños de ensayos clínicos, altos costos y bajo número de pacientes. Cientos de alelos del mutante están implicados en la mayoría de los LSDs. Las enfermedades se clasifican típicamente en 2 a 3 diferentes tipos clínicos según la gravedad. Por otra parte, la caracterización molecular del genotipo puede ayudar a predecir los resultados clínicos e informar a la atención de los pacientes. Por lo tanto, hemos desarrollado un ensayo de cultivo de célula simple basado en HEK293H las células con heterologously sobreexpresión las mutaciones identificadas en la enfermedad de Fabry y Pompe. Un análisis similar se ha introducido recientemente como prueba preclínica para identificar mutaciones susceptibles de terapia farmacológica de acompañante (PCT) en la enfermedad de Fabry. Este manuscrito describe un ensayo de cultivo de células modificadas que permiten una rápida evaluación fenotípica de variantes alélicas en la enfermedad de Fabry y Pompe a identificar a los pacientes elegibles para el PCT y puede ayudar en el desarrollo de nuevos pharmacochaperones.

El procedimiento de mutagénesis Para evaluar la eficiencia de mutagénesis GLA gen, las mutaciones se clasificaron en una de las siguientes categorías. Este enfoque para generar mutaciones reveló que cerca de 66,5% de las mutaciones de GLA se obtuvieron en el primer intento. Un 25% podría obtenerse después de un PCR de segunda ligeramente modificada.
Categoría 1: La mutagénesis PCR fu...

Watch this Scientific Journal Video about In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease at JoVE.com

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Existe una demanda para hacer clínico pruebas de una nueva clase de fármacos "huérfanos" llamadas chaperonas farmacológicas reproducible, rápida y eficiente. Desarrollamos un análisis basado en la cultura de célula simple, altamente estandarizados y versátil a pantalla para pacientes elegibles así como chaperonas farmacológicas novela drogas.

In Vitro Medición de la enzima a prueba chaperonas farmacológicas respuesta de Fabry y la enfermedad de Pompe

The use of personalized medicine to treat rare monogenic diseases like lysosomal storage disorders (LSDs) is challenged by complex clinical trial designs, ...

The overall goal of this amended cell culture protocol is to supply a rapid phenotypic assessment of allelic variance in Fabry and Pompe disease. This method can help to answer key questions in the field of lysosomal storage diseases, such as prognostic outcomes and therapeutic decisions. The main advantage of this technique is that it is highly reproducible and that it can aid in the development of novel drugs, such as pharmaco-chaperones.To carry out site-directed mutagenesis, begin by using the reference sequences NM 00169.2 and NM 00152.4 as templates for the mutagenesis of GLA and GAA genes, respectively. Use the free Primer Design tool to support primer design. Then, have a set of high-purity, salt-free primers synthesized by a commercial provider, with sense and antisense primers carrying one of the respective sequence modifications, central to their length, to individually introduce the mutation.Prepare the reaction mixture in a 50 microliter volume and run the PCR program using standard conditions provided by the manufacturer and as listed in the text protocol. Following PCR, add one microliter of Dpn1 restriction enzyme and continue to incubate the reaction vials at 37 degrees Celsius for one hour. After transforming the plasma DNA into competent E.coli cells and preparing plasmids of the desired transformance according to the text protocol, use a suitable molecular biology tool to analyze the sequence.When the desired mutation is detected and no further sequence abnormality compared to NM 000169.2 for alpha-galactosidase A or NM 000152.4 for acid alpha-galactosidase is seen, select the clone for transfection-grade plasmid purification. Determine the purity of the DNA by measuring the absorbance in a spectrophotometer. Following the cultivation of HEK293H cells in a T75 culture flask according to the text protocol, 24 hours prior to the transfection, use PBS without calcium or magnesium to wash the cells once.With 0.05%Trypsin-EDTA, harvest the cells and in the cavities of a 24-well culture plate use 500 microliters of DMEM supplemented with 10%FBS to seed 1.5 times 10 to the five cells. Carry out cell transfection according to the manufacturer's manual. Using a mixture of one microgram of plasmid DNA dissolved in 100 microliters of serum-free DMEM and 2.5 microliters of transfection reagent.Incubate the solution for 20 minutes at room temperature, then add it to the cells in a dropwise manner. After a period of four hours at 37 degrees Celsius and 5%CO2, remove the medium containing the transfection reagent and add 500 microliters of fresh DMEM with 10%FBS and 1%penicillin-streptomycin. As an option during this step, add DGJ or DNJ to the culture medium where intended.On the day of the harvest, remove the cells from the incubator. Then aspirate the medium and use PBS with calcium and magnesium to carefully wash the cells two times. This step is critical because DGJ and DNJ are inhibitors of both enzymes, and therefore any left over would invalidate the test.Following the wash, add 200 microliters of deionized water directly on top of the cells. Then rinse the cells from the plate and transfer them to a 1.5 milliliter reaction tube. Place the samples in an appropriate foam rack and vortex them for five seconds to make the lysis more efficient.Then alternate the samples between liquid nitrogen for 10 seconds and a room-temperature water bath until the thawing is complete. After repeating the homogenization procedure five times, spin the samples for five minutes at 10, 000g. Then transfer the supernatant into a new reaction tube.To carry out the BCA assay, prepare a fresh tube for each sample containing 40 microliters of deionized H20 and add 10 microliters of sample. Mix each solution by briefly vortexing and transfer 10 microliters of each sample in triplicate into the cavities of a 96-well plate. To prepare a standard curve, dilute a 2 milligram per milliliter BSA stock solution and deionized H2O according to the text protocol.After combining reagent A and reagent B, start the reaction by adding 200 microliters of the BCA reagent solution and incubate the samples in the dark at 37 degrees Celsius and 300 rpm on an orbital shaker for one hour. Then measure the absorbance at 560 nanometers in a plate reader. The samples typically contain between one and 1.5 micrograms of protein per microliter.Dilute the calculated amount of each sample and pipette it into fresh 1.5 milliliter reaction tubes to obtain 0.05 micrograms of alpha-galactosidase A or 0.5 micrograms of acid alpha-glucosidase per microliter of solution. Vortex the samples for five seconds again and pipette 10 microliters of this dilution in duplicate into a 96-well plate. Start the reactions by adding 20 microliters of the respective substrate solution.For alpha-galactosidase A, add two millimolar 4-methylumbelliferyl alpha-D galactopyranoside, or 4-MU-gal, in 0.06 molar phosphate-citrate buffer, pH 4.7. For acid alpha-glucosidase, add 2 millimolar 4-methylumbelliferyl alpha-D glucopyranoside, or 4-MU-glu, in 0.025 molar sodium acetate, pH 4.0. Incubate the enzyme reactions for one hour in the dark at 37 degrees Celsius and 300 rpm on an orbital shaker.Then terminate the reaction by adding 200 microliters of 1.0 molar pH 10.5-adjusted glycine sodium-hydroxide buffer. Prepare a standard curve of 4-MU from a 0.01 milligram per milliliter stock according to the text protocol and pipette 10 microliters of the solutions in duplicate into a 96-well plate. Add 200 microliters of the 1.0 molar glycine sodium-hydroxide buffer to each well in order to adjust the volume and pH.Finally, measure the enzyme activity in a florescence reader equipped with the appropriate filter set. And analyze the data using the appropriate software for the fluorescence-reader device. To assess the efficiency of GLA gene mutagenesis, the mutations were classified into three categories and revealed that about 66.5%were obtained in the first attempt.A further 25%could be obtained after a slightly modified second PCR. In category three, more effort, such as primer redesign, had to be undertaken to yield the desired clone. This table refers to the enzyme-activity measurement results for three alpha-galactosidase A and three acid alpha-glucosidase mutations either left untreated or treated with DGJ and DNJ.The data are displayed as absolute values for the substrate turnover and has relative values normalized to the wild-type enzyme. The absolute enzyme activity data was corrected for endogenous enzyme activity of the HEK293H cells using cells transfected with an empty pcDNA 3.1 vector. Enzyme activity values were normalized to wild-type enzyme from corresponding experiments, which explains the deviation of relative values between the different mutants.Once mastered, the post-cell culture fraction of this experiment, which represents most of the hands-on time, can be done within four hours. After its development, this technique paved the way for researchers in the field of lysosomal storage diseases to explore genotype-phenotype correlations in Fabry and Pompe disease. This protocol can aid in the development of novel drugs in lysosomal storage diseases.

Research

JoVE Journal

Medicine

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Making Sense of Listening: The IMAP Test Battery

Tener sentido de la escucha: la batería de pruebas IMAP

The ability to hear is only the first step towards making sense of the range of information contained in an auditory signal. Of equal importance are the ...

Investigación

Medicina

Acute Myocardial Infarction in Rats

Infarto agudo de miocardio en ratas

With heart failure leading the cause of death in the USA (Hunt), biomedical research is fundamental to advance medical treatments for cardiovascular ...

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Una estrategia para identificar mutaciones de novo en los trastornos comunes, tales como el autismo y la esquizofrenia

There are several lines of evidence supporting the role of de novo mutations as a mechanism for common disorders, such as autism and schizophrenia. First, ...

The Measurement and Treatment of Suppression in Amblyopia

La medición y tratamiento de la represión en la ambliopía

Amblyopia, a developmental disorder of the visual cortex, is one of the leading causes of visual dysfunction in the working age population. Current ...

A Simple Method of Mouse Lung Intubation

Un sencillo método de intubación ratón de pulmón

A  simple procedure to intubate mice for pulmonary function measurements would  have several advantages in longitudinal studies with limited numbers or  ...

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Desarrollo de un modelo basado en la rata alfa-sinucleína para la enfermedad de Parkinson mediante inyección estereotáctica de un vector viral adeno-asociado recombinante

In order to study the molecular pathways of Parkinson&#39;s disease (PD) and to develop novel therapeutic strategies, scientific investigators rely on ...

Repeated Measurement of Respiratory Muscle Activity and Ventilation in Mouse Models of Neuromuscular Disease

Repetida Medición de la actividad muscular respiratoria y ventilación en el ratón modelos de enfermedad neuromuscular

Accessory respiratory muscles help to maintain ventilation when diaphragm function is impaired. The following protocol describes a method for repeated ...

Neonatal Murine Cochlear Explant Technique as an In Vitro Screening Tool in Hearing Research

Neonatal Murine Cochlear Explant Technique as an In Vitro Screening Tool in Hearing Research

Técnica de Explante Coclear Murino Neonatal como<em&gt; In Vitro</em&gt; Herramienta de detección en la investigación de la audición

While there have been remarkable advances in hearing research over the past few decades, there is still no cure for Sensorineural Hearing Loss (SNHL), a ...

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Muestreo y extracción in situ de tumores cerebrales para el análisis de metabolómica y lipidómica

Despite the variety of tools available for cancer diagnosis and classification, methods that enable fast and simple characterization of tumors are still ...

A Neonatal BALB/c Mouse Model of Necrotizing Enterocolitis

Un modelo de ratón BALB/c neonatal de enterocolitis necrosante

Necrotizing enterocolitis (NEC) is the most severe gastrointestinal (GI) disease that often occurs in premature infants, especially very low birth weight ...